{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:50Z","timestamp":1793414150034,"version":"4.5.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic sclerosis (SSc) is a rare fibrotic rheumatic disease, associated with psychological distress and increased morbidity and mortality due to skin involvement and internal organ damage. The current understanding of the complex pathogenesis is yet incomplete and disease therapeutic algorithms are far from optimal. Immunologic aberrations are considered key factors for the disease, along with vascular involvement and excess fibrosis. Adaptive immunity and its specialized responses are an attractive research target and both T and B cells have been extensively studied in recent years. In the present review, the focus is placed on B cells in SSc. B cell homeostasis is deranged and B cell subsets exhibit an activated phenotype and abnormal receptor signaling. Autoantibodies are a hallmark of the disease and the current perception of their diagnostic and pathogenetic role is analyzed. In addition, B cell cytokine release and its effect on immunity and fibrosis are examined, together with B cell tissue infiltration of the skin and lung. These data support the concept of targeting B cells as part of the therapeutic plan for SSc through well designed clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2022.925741","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:23:06Z","timestamp":1655943786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":119,"title":["Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells"],"prefix":"10.3389","volume":"13","author":[{"given":"Konstantinos","family":"Melissaropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros I.","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic Sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in Mortality in Patients With Systemic Sclerosis Over 40 Years: A Systematic Review and Meta-Analysis of Cohort Studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current Concepts on the Pathogenesis of Systemic Sclerosis","author":"Truchetet","year":"2021","journal-title":"Clinic Rev Allerg Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S18145","article-title":"Vascular Involvement in Systemic Sclerosis (Scleroderma)","volume":"4","author":"Postlethwaite","year":"2011","journal-title":"JIR"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13238","article-title":"The Immunopathogenesis of Fibrosis in Systemic Sclerosis","volume":"195","author":"Brown","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000735","article-title":"Systemic Sclerosis Pathogenesis: Contribution of Recent Advances in Genetics","volume":"32","author":"Orvain","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2020.19131","article-title":"Putative Functional Pathogenic Autoantibodies in Systemic Sclerosis","volume":"7","author":"Benfaremo","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20274","article-title":"Altered Blood B Lymphocyte Homeostasis in Systemic Sclerosis: Expanded Naive B Cells and Diminished But Activated Memory B Cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheumatism"},{"key":"B9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated Serum BAFF Levels in Patients With Systemic Sclerosis: Enhanced BAFF Signaling in Systemic Sclerosis B Lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheumatism"},{"key":"B10","article-title":"Elevated Serum APRIL Levels in Patients With Systemic Sclerosis: Distinct Profiles of Systemic Sclerosis Categorized by APRIL and BAFF","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00496","article-title":"Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation","volume":"6","author":"Soto","year":"2015","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.015","article-title":"Altered B Lymphocyte Homeostasis and Functions in Systemic Sclerosis","volume":"17","author":"Forestier","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B13","first-page":"23","article-title":"Increased Expression Levels of Fc\u03b3riib on Na\u00efve and Double- Negative Memory B Cells in Patients With Systemic Sclerosis","volume":"119","author":"Yagi-Numata","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez244","article-title":"Distinctive Association of Peripheral Immune Cell Phenotypes With Capillaroscopic Microvascular Patterns in Systemic Sclerosis","volume":"58","author":"Kubo","year":"2019","journal-title":"Rheumatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686483","article-title":"Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients","volume":"12","author":"Simon","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12795","article-title":"CD21\u2013\/low B Cells in Human Blood are Memory Cells","volume":"185","author":"Thorarinsdottir","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108364","article-title":"CD21low B Cells in Systemic Sclerosis: A Possible Marker of Vascular Complications","volume":"213","author":"Marrapodi","year":"2020","journal-title":"Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/fq8tm9","article-title":"Regulatory B Cell Imbalance Correlates With Tfh Expansion in Systemic Sclerosis","author":"Ricard","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13604","article-title":"CD21low B Cells Are Predictive Markers of New Digital Ulcers in Systemic Sclerosis","volume":"205","author":"Visentini","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B Cells: Origin, Phenotype, and Function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis: BREG CELLS IN SYSTEMIC SCLEROSIS","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/fq8tm9","article-title":"Regulatory B Cell Imbalance Correlates With Tfh Expansion in Systemic Sclerosis","volume":"131","author":"Ricard","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased Levels of Regulatory B Cells in Patients With Systemic Sclerosis: Association With Autoantibody Production and Disease Activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948129","article-title":"Cytometry by Time of Flight Identifies Distinct Signatures in Patients With Systemic Sclerosis, Systemic Lupus Erythematosus and Sj\u00f6grens Syndrome","volume":"50","author":"Kroef","year":"2020","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01602","article-title":"Systemic Sclerosis Perturbs the Architecture of the Immunome","volume":"11","author":"Paleja","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B Cell Antigen Receptor Signaling 101","volume":"41","author":"Dalporto","year":"2004","journal-title":"Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0427-9","article-title":"B Cell Signaling in Context","volume":"20","author":"Kwak","year":"2019","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1074-7613(00)80094-1","article-title":"Modulation of B Lymphocyte Antigen Receptor Signal Transduction by a CD19\/CD22 Regulatory Loop","volume":"11","author":"Fujimoto","year":"1999","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative Genetic Variation in CD19 Expression Correlates With Autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4076-3","article-title":"Decreased CD22 Expression and Intracellular Signaling Aberrations in B Cells of Patients With Systemic Sclerosis","volume":"38","author":"Melissaropoulos","year":"2018","journal-title":"Rheumatol Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s Tyrosine Kinase in B Cells and Malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13075-020-02153-8","article-title":"Inhibition of Effector B Cells by Ibrutinib in Systemic Sclerosis","volume":"22","author":"Einhaus","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.22847","article-title":"B Cell Infiltration in Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheumatism"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.40016","article-title":"Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor \u03b2 and Activate Fibroblasts: IL-6 AND Tnf\u03b2 SECRETION BY SSc PERIPHERAL B LYMPHOCYTES","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","article-title":"Bronchoalveolar Lavage Fluid and Progression of Scleroderma Interstitial Lung Disease: Scleroderma Interstitial Lung Disease","volume":"6","author":"De Santis","year":"2012","journal-title":"Clin Respir J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200410","article-title":"Cellular Infiltrates in Scleroderma Skin","volume":"20","author":"Fleischmajer","year":"1977","journal-title":"Arthritis Rheumatism"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270607","article-title":"Lymphocytes in the Skin of Patients With Progressive Systemic Sclerosis","volume":"27","author":"Roumm","year":"1984","journal-title":"Arthritis Rheumatism"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and Cell Type-Specific Gene Expression Patterns in Scleroderma Skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin","volume":"3","author":"Milano","year":"2008","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1569-0","article-title":"Characterization of Inflammatory Cell Infiltrate of Scleroderma Skin: B Cells and Skin Score Progression","volume":"20","author":"Bosello","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global Skin Gene Expression Analysis of Early Diffuse Cutaneous Systemic Sclerosis Shows a Prominent Innate and Adaptive Inflammatory Profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220209","article-title":"Single-Cell Transcriptome Analysis Identifies Skin-Specific T-Cell Responses in Systemic Sclerosis","volume":"80","author":"Gaydosik","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as Predictive Tools in Systemic Sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/art.41153","article-title":"Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220402","article-title":"Molecular Basis for Clinical Diversity Between Autoantibody Subsets in Diffuse Cutaneous Systemic Sclerosis","volume":"80","author":"Clark","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa447","article-title":"Association of Differentially Expressed Genes and Autoantibody Type in Patients With Systemic Sclerosis","volume":"60","author":"Inamo","year":"2021","journal-title":"Rheumatology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.001","article-title":"Anti-Centromere Protein A Antibodies in Systemic Sclerosis: Significance and Origin","volume":"15","author":"Perosa","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218881","article-title":"Anti-Centromere Antibodies Target Centromere\u2013Kinetochore Macrocomplex: A Comprehensive Autoantigen Profiling","volume":"80","author":"Kajio","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.20515","article-title":"Direct Binding of Anti-DNA Topoisomerase I Autoantibodies to the Cell Surface of Fibroblasts in Patients With Systemic Sclerosis: Antifibroblast Autoantibodies in SSc","volume":"50","author":"H\u00e9nault","year":"2004","journal-title":"Arthritis Rheumatism"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.41403","article-title":"Association of Anti\u2013Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti\u2013Topoisomerase I\u2013Positive Systemic Sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.21646","article-title":"DNA Topoisomerase I Binding to Fibroblasts Induces Monocyte Adhesion and Activation in the Presence of Anti\u2013Topoisomerase I Autoantibodies From Systemic Sclerosis Patients","volume":"54","author":"H\u00e9nault","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13075-019-1931-x","article-title":"Antibodies Against Specific Extractable Nuclear Antigens (ENAs) as Diagnostic and Prognostic Tools and Inducers of a Profibrotic Phenotype in Cultured Human Skin Fibroblasts: Are They Functional","volume":"21","author":"Corallo","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3845-9","article-title":"Anti-CENP-B and Anti-TOPO-1-Containing Sera From Systemic Sclerosis-Related Diseases With Raynaud\u2019s Phenomenon Induce Vascular Endothelial Cell Senescence Not via Classical P53-P21 Pathway","volume":"37","author":"Shen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.587773","article-title":"Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification","volume":"7","author":"Yang","year":"2020","journal-title":"Front Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03112","article-title":"Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors","volume":"9","author":"Maria","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.1246886","article-title":"Association of the Autoimmune Disease Scleroderma With an Immunologic Response to Cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis","volume":"354","author":"Svegliati Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/art.24365","article-title":"Lack of Detection of Agonist Activity by Antibodies to Platelet-Derived Growth Factor Receptor \u03b1 in a Subset of Normal and Systemic Sclerosis Patient Sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/art.24381","article-title":"Lack of Evidence of Stimulatory Autoantibodies to Platelet-Derived Growth Factor Receptor in Patients With Systemic Sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.39125","article-title":"Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor \u03b1 Autoantibodies in Systemic Sclerosis: Epitope Specificity Of Anti-Pdgfr\u03b1 Autoantibodies In Ssc","volume":"67","author":"Moroncini","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ab.2017.04.011","article-title":"Characterization of Binding and Quantification of Human Autoantibodies to Pdgfr\u03b1 Using a Biosensor-Based Approach","volume":"528","author":"Moroncini","year":"2017","journal-title":"Analytical Biochem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12097.x","article-title":"Function Blocking Autoantibodies Against Matrix Metalloproteinase-1 in Patients With Systemic Sclerosis","volume":"120","author":"Sato","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02615.x","article-title":"Autoantibody Against Matrix Metalloproteinase-3 in Patients With Systemic Sclerosis","volume":"138","author":"Nishijima","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jdermsci.2008.04.013","article-title":"Autoantibodies Against Matrix Metalloproteinase-1 in Patients With Localized Scleroderma","volume":"52","author":"Tomimura","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0362","article-title":"Kinetics of Anti-Fibrillin-1 Autoantibodies in MCTD and CREST Syndrome","volume":"14","author":"Lundberg","year":"2000","journal-title":"J Autoimmun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4555","article-title":"Autoantibodies to Fibrillin-1 Activate Normal Human Fibroblasts in Culture Through the TGF- Pathway to Recapitulate the \u201cScleroderma Phenotype\u201d","volume":"175","author":"Zhou","year":"2005","journal-title":"J Immunol"},{"key":"B67","article-title":"Human Antibodies to Vascular Endothelium","volume":"9","author":"Lindqvist","year":"1971","journal-title":"Clin Exp Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-867.x","article-title":"Antibodies to Membranes of Endothelial Cells and Fibroblasts in Scleroderma","volume":"106","author":"Hill","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.02.006","article-title":"Anti-Endothelial Cell Antibodies From Patients With Limited Cutaneous Systemic Sclerosis Bind to Centromeric Protein B (CENP-B)","volume":"120","author":"Servettaz","year":"2006","journal-title":"Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2013.812080","article-title":"Functional Implications of IgG Anti-Endothelial Cell Antibodies in Pulmonary Arterial Hypertension","volume":"46","author":"Arends","year":"2013","journal-title":"Autoimmunity"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.11179","article-title":"In Vivo Analysis of the Apoptosis-Inducing Effect of Anti-Endothelial Cell Antibodies in Systemic Sclerosis by the Chorionallantoic Membrane Assay","volume":"48","author":"Worda","year":"2003","journal-title":"Arthritis Rheumatism"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of Functional Autoantibodies Against Vascular Receptors in Systemic Sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to Angiotensin and Endothelin Receptors in Systemic Sclerosis Induce Cellular and Systemic Events Associated With Disease Pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096545","article-title":"Muscarinic-3 Acetylcholine Receptor Autoantibody in Patients With Systemic Sclerosis: Contribution to Severe Gastrointestinal Tract Dysmotility","volume":"68","author":"Kawaguchi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(99)90184-1","article-title":"Myenteric Neuronal Antibodies in Scleroderma: Passive Transfer Evokes Alterations in Intestinal Myoelectric Activity in a Rat Model","volume":"133","author":"Eaker","year":"1999","journal-title":"J Lab Clin Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36057","article-title":"Antibody-Mediated Gastrointestinal Dysmotility in Scleroderma","volume":"123","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00286.2009","article-title":"Immunoglobulins From Scleroderma Patients Inhibit the Muscarinic Receptor Activation in Internal Anal Sphincter Smooth Muscle Cells","volume":"297","author":"Singh","year":"2009","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.151.9.4625","article-title":"Transforming Growth Factor-Beta 1 is Required for Secretion of IgG of All Subclasses by LPS-Activated Murine B Cells In Vitro","volume":"151","author":"Snapper","year":"1993","journal-title":"J Immunol"},{"key":"B80","first-page":"15","article-title":"Cytokine Imbalance in Patients With Systemic Sclerosis and Resilience: The Key Role of Interleukin-6","author":"Rojas","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1670062","article-title":"Biomarkers of Skin and Lung Fibrosis in Systemic Sclerosis","volume":"15","author":"Martinovi\u0107 Kaliterna","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/path.5680","article-title":"TGF-\u03b2 as a Driver of Fibrosis: Physiological Roles and Therapeutic Opportunities","volume":"254","author":"Budi","year":"2021","journal-title":"J Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.67209","article-title":"Single-Cell-Level Protein Analysis Revealing the Roles of Autoantigen-Reactive B Lymphocytes in Autoimmune Disease and the Murine Model","volume":"10","author":"Fukasawa","year":"2021","journal-title":"eLife"},{"key":"B84","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"and B-Cell Activating Factor Promote Collagen and Profibrotic Markers Expression by Dermal Fibroblasts in Systemic Sclerosis","volume":"15","author":"Fran\u00e7ois","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1038\/ncomms5092","article-title":"Human B Cells Induce Dendritic Cell Maturation and Favour Th2 Polarization by Inducing OX-40 Ligand","volume":"5","author":"Maddur","year":"2014","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/art.41798","article-title":"B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis","volume":"73","author":"Numajiri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2174\/0929867322666150209161224","article-title":"Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis","volume":"22","author":"Dimitroulas","year":"2015","journal-title":"CMC"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide Versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"New Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate Mofetil Versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease (SLS II): A Randomised Controlled, Double-Blind, Parallel Group Trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in Systemic Sclerosis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial","volume":"311","author":"Van Laar","year":"2014","journal-title":"JAMA - J Am Med Assoc"},{"key":"B92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.30.1.33","article-title":"Treatment of Systemic Sclerosis Associated Fibrotic Manifestations: Current Options and Future Directions","volume":"30","author":"Daoussis","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/art.24249","article-title":"B Cell Depletion With Rituximab in Patients With Diffuse Cutaneous Systemic Sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in Diffuse Cutaneous Systemic Sclerosis: An Open-Label Clinical and Histopathological Study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B Cell Depletion in Diffuse Progressive Systemic Sclerosis: Safety, Skin Score Modification and IL-6 Modulation in an Up to Thirty-Six Months Follow-Up Open-Label Trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle Study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"B98","article-title":"Effect of Long-Term Treatment With Rituximab on Pulmonary Function and Skin Fibrosis in Patients With Diffuse Systemic Sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A Multicenter, Open-Label, Comparative Study of B-Cell Depletion Therapy With Rituximab for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheumatism"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of Patients With Systemic Sclerosis Treated With Rituximab in Contemporary Practice: A Prospective Cohort Study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.08.004","article-title":"Rituximab as a Rescue Treatment Added on Mycophenolate Mofetil Background Therapy in Progressive Systemic Sclerosis Associated Interstitial Lung Disease Unresponsive to Conventional Immunosuppression","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheumatism"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous Cyclophosphamide vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatol (Oxf)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the Treatment of Systemic Sclerosis\u2013Related Interstitial Lung Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and Efficacy of Rituximab in Systemic Sclerosis: A Systematic Review and Meta-Analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107524","article-title":"Safety and Efficacy of Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis","volume":"95","author":"Xing","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05698-4","article-title":"Efficacy and Safety of Rituximab Therapy in Patients With Systemic Sclerosis Disease (SSc): Systematic Review and Meta-Analysis","volume":"40","author":"Moradzadeh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05542-1","article-title":"Efficacy and Safety of Rituximab on Lung and Skin Involvement in Systemic Sclerosis: A Systematic Review and Metaanalysis","volume":"40","author":"Borrirukwisitsak","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-021-00170-y","article-title":"Is Rituximab Effective for Systemic Sclerosis? A Systematic Review and Meta-Analysis","volume":"61","author":"de Figueiredo Caldas","year":"2021","journal-title":"Adv Rheumatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.33.1.1","article-title":"B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease","volume":"33","author":"Bounia","year":"2022","journal-title":"MJR"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e000384","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in Early Systemic Sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and Efficacy of Rituximab in Systemic Sclerosis (DESIRES): A Double-Blind, Investigator-Initiated, Randomised, Placebo-Controlled Trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"keac023","DOI":"10.1093\/rheumatology\/keac023","article-title":"Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: A Machine-Learning Analysis of the DesiReS Trial","volume":"12","author":"Ebata","year":"2022","journal-title":"Rheumatology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and Efficacy of B-Cell Depletion With Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0612ED","article-title":"A Phase-2 NIH-Sponsored Randomized Clinical Trial of Rituximab in SSC-PAH Did Not Reach Significance for its Endpoints: End of Story? Not So Fast","volume":"204","author":"Zhang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.09.003","article-title":"Is There a Role for B-Cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature","volume":"40","author":"Daoussis","year":"2010","journal-title":"Semin Arthritis Rheumatism"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/214013","article-title":"B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence","volume":"2011","author":"Daoussis","year":"2011","journal-title":"Int J Rheumatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05665-z","article-title":"B Cells in Systemic Sclerosis: From Pathophysiology to Treatment","volume":"40","author":"Melissaropoulos","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/ar3879","article-title":"B-Cell Depletion Therapy in Patients With Diffuse Systemic Sclerosis Associates With a Significant Decrease in PDGFR Expression and Activation in Spindle-Like Cells in the Skin","volume":"14","author":"Daoussis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1017-y","article-title":"B Cell Depletion Therapy Upregulates Dkk-1 Skin Expression in Patients With Systemic Sclerosis: Association With Enhanced Resolution of Skin Fibrosis","volume":"18","author":"Daoussis","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of Canonical Wnt Signalling Is Required for TGF-\u03b2-Mediated Fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat Commun"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04357-x","article-title":"Targeting Very Early Systemic Sclerosis: A Case-Based Review","volume":"39","author":"Melissaropoulos","year":"2019","journal-title":"Rheumatol Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.925741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T22:09:12Z","timestamp":1675894152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.925741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":121,"alternative-id":["10.3389\/fimmu.2022.925741"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.925741","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"article-number":"925741"}}